Author: admin

  • Stonepeak Launches Middle East Renewables Platform WahajPeak

    Stonepeak Launches Middle East Renewables Platform WahajPeak

    Platform to be led by industry veteran Mothana Qteishat

    ABU DHABI & NEW YORK – August 18, 2025 – Stonepeak, a leading alternative investment firm specializing in infrastructure and real assets, today announced the launch of WahajPeak (the “Platform”), Stonepeak’s inaugural renewable energy platform in the Middle East dedicated to securing and developing high-quality renewable energy projects in the region and beyond.

    WahajPeak will invest in utility-scale renewable energy projects including solar, wind, and battery storage developments across the Gulf Cooperation Council and the broader Middle East. The Platform’s strategy is supported by constructive policy tailwinds across the region, including national energy agendas focused on decarbonization, energy diversification, and grid modernization. WahajPeak will be led by Mothana Qteishat, former Vice President at Jinko Power, who brings 17 years of experience in the Middle East’s renewable energy sector. He has led the development and delivery of more than 5 GW of solar capacity, including the delivery of two of the world’s largest solar projects at their time of operation. He will be supported by a seasoned team with more than 100 years of combined experience and a proven execution track record.

    Mothana Qteishat commented, “Governments across the Middle East and North Africa are targeting the deployment of approximately 175 GW of renewable energy capacity by 2030, creating a rapidly growing need for reliable, utility-scale infrastructure. With the WahajPeak team’s strong execution track record and Stonepeak’s deep experience in renewable energy investment and platform building, we are well-positioned to meet this demand. We’ve designed WahajPeak to scale and adapt over time, in step with the region’s evolving energy landscape, and we are excited to work closely with our stakeholders to seize the significant opportunities ahead.”

    Hajir Naghdy, Senior Managing Director and Head of Asia and the Middle East at Stonepeak, said, “Stonepeak has solidified its presence in the Middle East through dedicated boots on the ground in Riyadh and Abu Dhabi, and our previously announced partnership with The Arab Energy Fund. With the establishment of WahajPeak, we are furthering our commitment to the region. We look forward to leveraging our local presence and significant experience building and scaling pan-regional platforms as we work with Mothana and team to grow WahajPeak.”

    Ryan Chua, Senior Managing Director at Stonepeak, added, “WahajPeak is a great example of Stonepeak’s approach to platform creation—combining exceptional talent with long-term capital, and our sector capabilities and network, to deliver essential infrastructure—making it a natural fit for our global renewables strategy. We have the utmost confidence in Mothana and the WahajPeak team, whose extensive experience and expertise in the region will be invaluable as we look to support the region’s energy transformation.”

    Select examples of Stonepeak’s platform creation experience include Stonepeak’s Asia Energy Storage Platform, Peak Energy, and Synera Renewable Energy, which are all dedicated to the development, ownership, and operation of renewable assets in Asia. Stonepeak has also supported the development and operation of distributed solar generation assets in North America through its platform Madison Energy Investments, which the firm fully realized in 2023. Most recently, Stonepeak has launched two new platforms including JouleTerra, a European renewables land aggregation platform, and Longview Infrastructure, a North American transmission development and investment platform. Through these platforms and other investments currently backed by Stonepeak, the firm has a total of 10.4 GW of renewable energy in operations, under construction, or in development across wind, solar, and battery energy storage systems.

    About Stonepeak
    Stonepeak is a leading alternative investment firm specializing in infrastructure and real assets with approximately $76.3 billion of assets under management. Through its investment in defensive, hard-asset businesses globally, Stonepeak aims to create value for its investors and portfolio companies, with a focus on downside protection and strong risk-adjusted returns. Stonepeak, as sponsor of private equity and credit investment vehicles, provides capital, operational support, and committed partnership to grow investments in its target sectors, which include transport and logistics, digital infrastructure, energy and energy transition, and real estate. Stonepeak is headquartered in New York with offices in Houston, Washington, D.C., London, Hong Kong, Seoul, Singapore, Sydney, Tokyo, Abu Dhabi, and Riyadh. For more information, please visit www.stonepeak.com.

    Contacts
    Kate Beers / Maya Brounstein
    corporatecomms@stonepeak.com
    +1 (646) 540-5225

    Continue Reading

  • Researchers in Australia uncovers key mechanism behind breast cancer treatment resistance-Xinhua

    SYDNEY, Aug. 18 (Xinhua) — Researchers in Australia have identified a key mechanism behind treatment resistance in estrogen receptor-positive (ER+) breast cancer, the most common subtype worldwide.

    The study revealed why some breast cancers resist treatment, potentially opening the door to more effective therapies for patients, according to a statement released Monday by the Sydney-based Garvan Institute of Medical Research.

    Scientists found that inactivation of a stress pathway makes ER+ breast cancer cells ignore stress signals and evade treatment, said the study published in Italy’s Journal of Experimental & Clinical Cancer Research.

    The team found that inactivating the JNK pathway enables cancer cells to resist endocrine therapy combined with CDK4/6 inhibitors, a common first-line treatment for high-risk patients.

    The JNK pathway acts as a cellular alarm, triggering damaged cells to stop dividing or self-destruct in response to stress, such as cancer treatments, said the study.

    “When we knocked out genes involved in the JNK pathway, cancer cells continued to grow despite treatment…These cells also spread to form more metastases in preclinical models,” said the study’s first author Sarah Alexandrou from the Garvan Institute and Australia’s University of New South Wales (UNSW).

    This resistance was observed both in laboratory experiments and in tumor samples from patients, where low JNK activity was correlated with poor response to therapy, the study showed.

    Co-author Associate Professor Liz Caldon from the Garvan Institute and the UNSW highlighted that screening for JNK pathway activity could predict which breast cancer patients won’t benefit from standard therapy, enabling more personalized treatment. ■

    Continue Reading

  • Better control of childhood EoE-associated inflammation reduces esophagus stiffening and complications

    Better control of childhood EoE-associated inflammation reduces esophagus stiffening and complications

    Researchers from Children’s Hospital of Philadelphia (CHOP) and Children’s Hospital Colorado have found that better control of chronic eosinophilic esophagitis (EoE)-associated inflammation during childhood leads to less stiffening of the esophagus, resulting in fewer disease complications. Using Endoluminal functional imaging (FLIP), the study team suggests this could be a key marker for assessing disease severity and progression. The findings were published online today by the journal Gastroenterology.

    EoE is a chronic allergic inflammatory disease of the esophagus, the muscular tube that carries food from the throat to the stomach. Children can experience nausea, regurgitation, vomiting, abdominal pain and a burning feeling like acid reflux. They may also have difficulty swallowing and gag frequently. Often, they can experience dysphagia, which is when it feels like something is stuck in their throat. If EoE goes untreated, the esophagus may narrow because of scarring, a phenomenon known as stricture.

    Chronic EoE-associated inflammation can lead to progressive tissue remodeling and fibrostenosis, or the narrowing of the esophagus. While clinicians recognize the severity of the disease, long-term studies looking at disease progression over time, and the impact of controlling the disease from a young age, is relatively unknown.

    This is the first study to follow kids overtime (with these endoscopic assessments) and evaluate the patients who are at the highest risk of complications. With the recent FDA approval of two medications for EoE, having this data could help identify the patients who could benefit from these therapies the most and observe improvement at a histologic level over time.”


    Amanda Muir, MD, co-senior study author, pediatric gastroenterologist, Division of Gastroenterology, Hepatology and Nutrition at CHOP

    Researchers at CHOP and Children’s Hospital Colorado launched a longitudinal study to evaluate long-term changes in esophageal distensibility, or the ability of the esophagus to expand, in pediatric patients between the ages of 3 and 18 years old. Symptomatic, endoscopic and histologic data were collected at each visit during the study. A total of 112 patients with EoE were included with a median follow-up time of 11 months, some followed for over 4 years.

    “Following children living with EoE over time has given us a clearer picture of how inflammation affects the esophagus and how treating it can improve the esophagus and outcomes for patients,” said Calies Menard-Katcher, MD, co-senior study author and Associate Director of Clinical Research for the Gastrointestinal Eosinophilic Diseases Program at Children’s Hospital Colorado. “It’s exciting to see these results confirm what we’ve suspected in caring for patients – and they may even help us spot those at risk for more severe disease.”

    The study found that patients with tissue samples showing a response to treatment demonstrated the most improvement in distensibility over time. After adjusting for different factors, the study found that patients with lower esophageal distensibility had increased odds of patient-reported dysphagia, or difficulty swallowing. Patients with fibrostenosis were generally diagnosed at an older age, had the disease for a longer period and showed reduced esophageal flexibility.

    Measuring distensibility at baseline predicted the need for future dilation in patients with strictures.

    The authors suggest that further studies that examine the disease from a molecular level could help them understand which patients may be at highest risk of severe disease and could benefit from a variety of treatment strategies.

    This study was supported by the National Institutes of Health grants R01DK124266-01, K23DK109263 and R21TR003039.

    Kennedy et al, “Histologic response is associated with improved esophageal distensibility and symptom burden in pediatric eosinophilic esophagitis.” Gastroenterology. Online August 15, 2025. DOI: 10.1053/j.gastro.2025.07.042.

    Source:

    Children’s Hospital of Philadelphia

    Journal reference:

    Kennedy, K., et al. (2025). Histologic response is associated with improved esophageal distensibility and symptom burden in pediatric eosinophilic esophagitis. Gastroenterology. doi.org/10.1053/j.gastro.2025.07.042.

    Continue Reading

  • Strange new shapes may rewrite the laws of physics

    Strange new shapes may rewrite the laws of physics

    How can the behavior of elementary particles and the structure of the entire universe be described using the same mathematical concepts? This question is at the heart of recent work by the mathematicians Claudia Fevola from Inria Saclay and Anna-Laura Sattelberger from the Max Planck Institute for Mathematics in the Sciences, recently published in the Notices of the American Mathematical Society.

    To the point:

    • Bridging mathematics and physics: The study explores how algebraic and one of the key players in the flourishing field of positive geometry unify physics from subatomic particles to galaxies.
    • Beyond Feynman diagrams: Positive geometry offers a complementary perspective to traditional quantum field theory methods — providing a geometric framework for describing particle interactions alongside Feynman diagrams.
    • From particle collisions to the Big Bang: Tools from algebraic geometry, D-module theory, and combinatorics drive this interdisciplinary progress — helping to decode the fundamental structures of particle interactions and the universe’s earliest states.

    Mathematics and physics share a close, reciprocal relationship. Mathematics offers the language and tools to describe physical phenomena, while physics drives the development of new mathematical ideas. This interplay remains vital in areas such as quantum field theory and cosmology, where advanced mathematical structures and physical theory evolve together.

    In their article, the authors explore how algebraic structures and geometric shapes can help us understand phenomena ranging from particle collisions such as happens, for instance, in particle accelerators to the large-scale architecture of the cosmos. Their research is centered around algebraic geometry. Their recent undertakings also connect to a field called positive geometry – an interdisciplinary and novel subject in mathematics driven by new ideas in particle physics and cosmology. This field was inspired by the geometrical concept of positive geometry which expands the standard Feynman diagram approach in particle physics by representing interactions as volumes of high-dimensional geometric objects, such as the amplituhedron, as introduced by the theoretical physicists Nima Arkani-Hamed and Jaroslav Trnka in 2013. It carries a rich combinatorial structure and offers an alternative, potentially simpler way to compute scattering amplitudes, from which one can derive probabilities of scattering events.

    This approach has far-reaching implications that go beyond particle physics. In cosmology, scientists are using the faint light of the cosmic microwave background and the distribution of galaxies to infer what shaped the early universe. Similar mathematical tools are now being applied. For instance, cosmological polytopes, which are themselves positive geometries, can represent correlations in the universe’s first light and help reconstruct the physical laws that governed the birth of the cosmos.

    A Geometry for the Universe

    The article highlights that positive geometry is not a niche mathematical curiosity but a potential unifying language for form branches of theoretical physics. These geometric frameworks naturally encode the transfer of information between physical systems, for example, by mapping concrete, sensory-based concepts to abstract structures, a process that mirrors how humans metaphorically understand the world.

    The mathematics behind this is sophisticated and spans multiple disciplines. The authors draw on algebraic geometry, which defines shapes and spaces through solutions to systems of polynomial equations, algebraic analysis, which studies differential equations through mathematical objects called D-modules, and combinatorics, which describes the arrangements and interactions within these structures.

    The formal objects under consideration, such as Feynman integrals, generalized Euler integrals, or canonical forms of positive geometries, are not merely mathematical abstractions. They correspond to observable phenomena in high-energy physics and cosmology, enabling precision computations of particle behavior and cosmic structures alike.

    Bridging Scales with Mathematics

    The study presents an approach with broad applicability and scalability. Scattering processes are often illustrated using Feynman diagrams. Feynman’s approach in the study of scattering amplitudes boils down to the study of intricate integrals associated to such diagrams. Algebraic geometry provides a range of tools for systematically investigating these integrals.

    The graph polynomial of a Feynman diagram is defined in terms of the spanning trees and forests of the underlying graph. The associated Feynman integral can be expressed as a Mellin transform of a power of this graph polynomial, interpreted as a function of its coefficients. These coefficients, however, are constrained by the underlying physical conditions. Feynman integrals are therefore closely connected to generalized Euler integrals, specifically through restrictions to the relevant geometric subspaces. One way to study these holonomic functions is via the linear differential equations they satisfy, which are D-module inverse images of hypergeometric D-modules. Constructing these differential equations explicitly, however, remains challenging. In theoretical cosmology, correlation functions in toy models also take the form of such integrals, with integrands arising from hyperplane arrangements.

    The complement of the algebraic variety defined by the graph polynomial in an algebraic torus is a very affine variety, and the Feynman integral can be viewed as the pairing of a twisted cycle and cocycle of this variety. Its geometric and (co-)homological properties reflect physical concepts such as the number of master integrals. These master integrals form a basis for the space of integrals when the kinematic parameters vary, and the size of this basis is, at least generically, equal to the signed topological Euler characteristic of the variety.

    A Field in Motion

    Fevola and Sattelberger’s work reflects a growing international effort, supported by the ERC synergy grant UNIVERSE+ of Nima Arkani-Hamed, Daniel Baumann, and Johannes Henn, Bernd Sturmfels. It brings together mathematics, particle physics, and cosmology focusing on precisely these connections between algebra, geometry, and theoretical physics. “Positive geometry is still a young field, but it has the potential to significantly influence fundamental research in both physics and mathematics,” the authors emphasize. “It is now up to the scientific community to work out the details of these emerging mathematical objects and theories and to validate them. Encouragingly, several successful collaborations have already laid important groundwork.”

    The recent developments are not only advancing our understanding of the physical world but also pushing the boundaries of mathematics itself. Positive geometry is more than a tool. It is a language. One that might unify our understanding of nature at all scales.

    Continue Reading

  • Wegovy Approved for MASH With Fibrosis, No Cirrhosis

    Wegovy Approved for MASH With Fibrosis, No Cirrhosis

    On Friday, the FDA granted accelerated approval to Novo Nordisk’s Wegovy for the treatment of metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis but without cirrhosis.

    The once-weekly 2.4 mg semaglutide subcutaneous injection is given in conjunction with a reduced calorie diet and increased physical activity.

    Among people living with overweight or obesity globally, 1 in 3 also have MASH.

    The accelerated approval was based on part-one results from the ongoing two-part, phase-3 ESSENCE trial, in which Wegovy demonstrated a significant improvement in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis, compared with placebo at week 72. Those results were published online in April in The New England Journal of Medicine.

    For the trial, 800 participants were randomly assigned to either Wegovy (534 participants) or placebo (266 participants) in addition to lifestyle changes. The mean age was 56 years and the mean BMI was 34. Most patients were white individuals (67.5%) and women (57.1%), and 55.9% of the patients had type 2 diabetes; 250 patients (31.3%) had stage II fibrosis and 550 (68.8%) had stage III fibrosis. Participants were on stable doses of lipid-lowering, glucose-management, and weight-loss medications.

    At week 72, the first primary endpoint showed 63% of the 534 people treated with Wegovy achieved resolution of steatohepatitis and no worsening of liver fibrosis compared with 34% of 266 individuals treated with placebo — a statistically significant difference.

    The second primary endpoint showed 37% of people treated with Wegovy achieved improvement in liver fibrosis and no worsening of steatohepatitis compared with 22% of those treated with placebo, also a significant difference.

    A confirmatory secondary endpoint at week 72 showed 33% of patients treated with Wegovy achieved both resolution of steatohepatitis and improvement in liver fibrosis compared with 16% of those treated with placebo — a statistically significant difference in response rate of 17%.

    In addition, 83.5% of the patients in the semaglutide group maintained the target dose of 2.4 mg until week 72.

    Wegovy is also indicated, along with diet and physical activity, to reduce the risk for major cardiovascular events in adults with known heart disease and with either obesity or overweight. It is also indicated for adults and children aged 12 years or older with obesity, and some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off.

    What’s Next for Wegovy?

    In February 2025, Novo Nordisk filed for regulatory approval in the EU, followed by regulatory submission in Japan in May 2025. Also in May, the FDA accepted a filing application for oral semaglutide 25 mg.

    Furthermore, “There’s an expected readout of part 2 of ESSENCE in 2029, which aims to demonstrate treatment with Wegovy lowers the risk of liver-related clinical events, compared to placebo, in patients with MASH and F2 or F3 fibrosis at week 240,” a Novo Nordisk spokesperson told Medscape Medical News.

    Although the company has the technology to produce semaglutide as a pill or tablet, she said, “the US launch of oral semaglutide for obesity will be contingent on portfolio prioritization and manufacturing capacity.” The company has not yet submitted the 50 mg oral semaglutide to regulatory authorities.

    “The oral form requires more active pharmaceutical ingredient (API),” she noted. “Given that we have a fixed amount of API, the injectable form enables us to treat more patients. We are currently expanding our oral and injectable production capacities globally with the aim of serving as many patients as possible. It requires time to build, install, validate, and ramp-up these production processes.”

    Marilynn Larkin, MA, is an award-winning medical writer and editor whose work has appeared in numerous publications, including Medscape Medical News and its sister publication MDedge, The Lancet (where she was a contributing editor), and Reuters Health.

    Continue Reading

  • Dogs Able to Sniff Out Parkinson’s Before Symptoms Appear

    Dogs Able to Sniff Out Parkinson’s Before Symptoms Appear

    Dogs can be trained to identify individuals with Parkinson’s disease (PD) by sniffing out a disease-specific odor in skin swabs with up to 98% specificity and 80% sensitivity, a recent study suggested.

    The findings may help inform key biomarkers for PD before symptoms appear. There is currently no single diagnostic test for PD, and reported estimates show roughly a quarter of patients are misdiagnosed.

    “Sensitivity levels of 70% and 80% are well above chance, and I believe that dogs could help us to develop a quick noninvasive, and cost-effective method to identify patients with Parkinson’s disease,” lead investigator Nicola Rooney, associate professor at Bristol Veterinary School at the University of Bristol, Bristol, England, said in a news release.

    The study was published online on July 14 in the Journal of Parkinson’s Disease.

    The Nose Knows

    Previous studies have shown that dogs can detect disease-specific odors in human breath or urine in patients with cancer, diabetes, and even posttraumatic stress disorder. This study adds to the growing evidence they can also identify PD.

    Seborrheic dermatitis and increased sebum production are premotor signs of PD. Previous research published last year by a nonprofit Parkinson’s organization based in Washington showed that various breeds of dogs can be trained to recognize sebum unique to PD patients. This led the UK-based researchers to suspect sebum could be used as an indicator of PD.

    For this double-blind, randomized controlled trial, investigators collected dry skin swabs from 130 patients with PD and 175 individuals without the condition. Of these, 205 swabs were used for training dogs from the organization Medical Detection Dogs. For double-blind testing, 40 samples were from patients who didn’t use drugs for PD (42.5% women; mean age, 69.6 years), and 60 samples were from individuals without PD.

    After 38-53 weeks of training, a Golden Retriever named Bumper and a Black Labrador named Peanut were shown samples on four stands in a line. In each line, there was either one positive sample or all controls. Both the trainer and experimenter were blind to the location of positive or negative samples. Computer software confirmed whether the dog’s response was correct.

    If the dog was unsure, samples were retested in new lines until a clear decision was made. Dogs were rewarded for correctly identifying a positive or negative sample.

    The dogs showed high specificity by correctly ignoring 90% and 98.3% of swabs from the control group and high sensitivity by correctly identifying 70% and 80% of the swabs from patients with PD (P < .0001). Of note, the Labrador had 15 weeks more training than the Golden Retriever and achieved the higher of the two results.

    “While we do not envisage dogs being diagnostic, they could potentially, with refinements, help to validate methods of clinical utility…and aid rapid screening and diagnosis,” the investigators wrote.

    The authors declared having no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

    Continue Reading

  • Ticket info: Newcastle United v Arsenal

    Ticket info: Newcastle United v Arsenal

    Below is ticketing information for our Premier League fixture against Newcastle United at St. James’ Park on Sunday, September 28 at 16:30 pm.

    We have received an allocation of 3,204 tickets for this fixture, which will be located in the Leazes stand. The full visiting allocation at St. James’ Park is also a safe standing area.

    All tickets for this game will be NFC Digital Passes and will be sent to each lead client and must be added to a mobile device prior to arrival at St. James’ Park. Please ensure that your email address details are up to date. Tickets will be sent on Tuesday, September 23. If you have not received your tickets, by Thursday, September 25, please contact our Supporter Services Team on 020 7619 5000 (option 1).

    Supporters aged 14 and under must be accompanied by an adult aged 18 or over.

    Please see Newcastle United Football Club’s guide for Visiting Supporters Information.

    We ask that you only purchase a ticket if you are planning to attend the match. Our goal is to ensure that as many supporters as possible have the chance to attend this game, and that our away support remains vibrant and passionate. 

    If you fail to successfully scan the relevant away match ticket at the turnstile of the hosting club’s ground, resulting in the ticket not being used, we will remove any away loyalty points that have been credited to your membership account for the relevant away game. The club also reserves the right to implement further away point removals for repeated occurrences as set out under section 3.8 of the Arsenal Away Match Ticket Terms and Conditions Season 2025-2026.

    AWAY TICKET EXCHANGE

    As part of our continued efforts to improve the ticketing experience for our supporters, we are pleased to announce a new Away Ticket Exchange service replacing Away Ticket Transfer for the 2025-2026 season.

    The Away Ticket Exchange service will open once the relevant away fixture has sold out.

    Ticket collections will continue to be enforced along with the Away Ticket Exchange service, as part of our ongoing efforts to ensure that genuine Arsenal supporters are using these tickets. Those supporters who have been informed to collect their tickets for this match, will be sent an email in advance of the date of the game with all the relevant ticket collection details.  

    Supporters collecting duplicate tickets on the day of the fixture, will be required to provide photo ID. The ID must match the name on the assigned ticket and photographs of ID are not valid. Third party ticket collections are also not permitted.  

    TICKET PRICES

    Ticket Type  Ticket Price  Accessibility Ticket Price 
    Adult  £30.00  £15.00 
    65 and over £27.00  £13.50 
    Full Time Student  £27.00 £13.50
    Junior (under 18) £22.00 £11.00

     

    The disability access ticket price includes a complimentary personal assistant ticket, which is subject to eligibility.  

    Information for Disability Access members 

    Members purchasing concession-priced tickets must bring ID on the day of the game, as you may be required to produce this on entry to the visiting stadium.

    SALES PHASES

    Sales Phase  Who can Buy  Points Required  Sale Date  Sale Time 
    No. 1 Platinum, Gold & Travel Club Members   45+ 26/08/2025 10am
    No. 2  Platinum, Gold & Travel Club Members   35+  27/08/2025  10am 

     

    All tickets and sale phases are subject to availability. 

     You can purchase your seats online (booking fees apply). You must quote the following information: 

    A valid password 

    A valid email address 

    Platinum, Gold or Travel Club Membership number/s 

    Credit/debit card details

    AWAY TRAVEL

    We are pleased to offer our supporters coach travel for this fixture at a rate of £30 per person.

    For more information and to purchase your travel for this fixture after completing your ticket booking, please click here. 

    Copyright 2025 The Arsenal Football Club Limited. Permission to use quotations from this article is granted subject to appropriate credit being given to www.arsenal.com as the source.

    Continue Reading

  • Increased construction in the Himalayas risks more deadly flash floods – Mongabay

    1. Increased construction in the Himalayas risks more deadly flash floods  Mongabay
    2. Uttarakhand flash floods: One dead, 66 still missing as rescue efforts continue  BBC
    3. Warnings Ignored  The Statesman
    4. Channel widened to drain artificial lake formed after Harsil mudslide  The Times of India
    5. Expert Team Rules Out Glacial Lake Burst Theory In Dharali Disaster  ETV Bharat

    Continue Reading

  • Gabby Logan’s ‘dip-dye’ sleeves revolutionise the classic shirt in her first outing since new job debut

    Gabby Logan’s ‘dip-dye’ sleeves revolutionise the classic shirt in her first outing since new job debut

    Who knew that the classic white shirt was due a new lease of life? Well, it appears Gabby Logan did, by choosing a striking short-sleeved shirt with vibrant green dip-dye detailing, pairing it with a matching skirt which was also dyed around the hem.

    Gabby was all smiles as she stepped out in the stylish ensemble, snapped for the first time since her debut appearance in her new job. Earlier this year, it was announced that Gabby would be joining BBC’s Match of the Day line up and, on Saturday (16 August), she presented on her first episode.

    MAHI//BACKGRID

    The presenter was spotted out and about in London wearing her white shirt and midi skirt combo, with each piece featuring a watercolour-style band of green. The matching set is a high street find from Arket. The best news? Both pieces are currently on sale and still in stock (at time of writing) – although some style have begun to sell out already.

    Printed Shirt

    Printed Shirt

    Printed Midi-Skirt

    Printed Midi-Skirt

    Ahead of starting her new position, Gabby took a much needed holiday to Greece. Over on Instagram, she shared snaps of her break away, describing the holiday as ‘ridiculously lovely.’

    Returning from her trip last week she said she was feeling ‘rested, recharged and raring to go.’, The photos show Gabby enjoying sunsets, blue skies and swimming pools with family and friends – including fellow sports presenter Kirsty Gallacher.

    In the post, the pair are snapped laughing together arm in arm in the last of the evening sun wearing matching black dresses. Kirsty shared snaps of her own from the trip admitting she was ‘missing holiday LOLs with the girls’ now she was back.


    Continue Reading

  • Pakistan reports 2 new polio cases, total reaches 21 in 2025-Xinhua

    ISLAMABAD, Aug. 18 (Xinhua) — Pakistan has confirmed two new cases of wild poliovirus type 1 (WPV1), bringing the total number of infections in the country this year to 21, health authorities said Monday.

    According to the Regional Reference Laboratory for Polio Eradication at the National Institute of Health in Islamabad, the new cases were detected in Kohistan District, northwest Khyber Pakhtunkhwa (KP) province, and Badin District, southern Sindh province.

    So far in 2025, KP has reported 13 cases, Sindh has reported six, while eastern Punjab and the northern Gilgit-Baltistan region have each recorded one case.

    Authorities said Pakistan will hold a sub-national polio campaign from Sept. 1 to 7 to vaccinate over 28 million children under five in 99 districts, urging parents to ensure multiple doses of oral vaccine for protection against the incurable, potentially paralyzing disease.

    Pakistan and its neighboring country Afghanistan remain the only two countries where wild poliovirus is still endemic. ■

    Continue Reading